OncoCyte Co. (NASDAQ:OCX) Major Shareholder Patrick W. Smith Buys 5,669 Shares

OncoCyte Co. (NASDAQ:OCX) major shareholder Patrick W. Smith purchased 5,669 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were purchased at an average price of $2.08 per share, for a total transaction of $11,791.52. Following the purchase, the insider now owns 1,779,572 shares of the company’s stock, valued at approximately $3,701,509.76. This trade represents a 0.32 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

OncoCyte Price Performance

Shares of OCX opened at $2.20 on Thursday. The company’s fifty day moving average price is $2.42 and its 200-day moving average price is $2.85. OncoCyte Co. has a 1-year low of $1.97 and a 1-year high of $3.57.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.54). OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The firm had revenue of $0.12 million for the quarter. During the same quarter in the previous year, the firm posted ($0.57) EPS. As a group, equities research analysts predict that OncoCyte Co. will post -2.57 EPS for the current fiscal year.

Hedge Funds Weigh In On OncoCyte

An institutional investor recently raised its position in OncoCyte stock. FNY Investment Advisers LLC lifted its holdings in OncoCyte Co. (NASDAQ:OCX) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 49,377 shares of the company’s stock after acquiring an additional 6,481 shares during the quarter. FNY Investment Advisers LLC owned 0.29% of OncoCyte worth $117,000 as of its most recent SEC filing. Institutional investors and hedge funds own 55.35% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on OCX. Needham & Company LLC reissued a “buy” rating and set a $4.25 price target on shares of OncoCyte in a research report on Wednesday, November 13th. StockNews.com assumed coverage on OncoCyte in a research note on Monday. They set a “sell” rating on the stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.